Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €8.50 EUR
Change Today +2.37 / 38.58%
Volume 3.7K
APS On Other Exchanges
As of 3:38 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

ariad pharmaceuticals inc (APS) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/24/15 - €9.09
52 Week Low
10/14/14 - €3.85
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

ariad pharmaceuticals inc (APS) Related Businessweek News

No Related Businessweek News Found

ariad pharmaceuticals inc (APS) Details

ARIAD Pharmaceuticals, Inc., an oncology company, engages in the discovery, development, and commercialization of medicines for cancer patients. The company offers Iclusig (ponatinib), a tyrosine kinase inhibitor (TKI) for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States, Europe, and other territories. It also develops Brigatinib, an investigational inhibitor of anaplastic lymphoma kinase for the treatment of various patients with a form of non-small cell lung cancer; and AP32788, an orally active TKI for treating non-small cell lung cancer and various other solid tumors. The company sells and markets Iclusig through specialty pharmacies and specialty distributors in the United States. It has license agreements with Medinol Ltd. and ICON Medical Corp. to develop and commercialize stents and other medical devices to deliver ridaforolimus. ARIAD Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Cambridge, Massachusetts.

379 Employees
Last Reported Date: 03/2/15
Founded in 1991

ariad pharmaceuticals inc (APS) Top Compensated Officers

Principal Founder, Chairman, Chief Executive ...
Total Annual Compensation: $1.4M
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: $676.0K
Chief Scientific Officer and President of Res...
Total Annual Compensation: $858.0K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $683.4K
Senior Vice President of Regulatory Affairs a...
Total Annual Compensation: $647.0K
Compensation as of Fiscal Year 2014.

ariad pharmaceuticals inc (APS) Key Developments

Baxalta Reportedly In Talks To Buy Ariad

Baxalta Incorporated (NYSE:BXLT) is in talks to buy Ariad Pharmaceuticals Inc. (NasdaqGS:ARIA), Bloomberg reported.

ARIAD Pharmaceuticals Announces First Patient Treated in Phase 2 Dose-Ranging Optic Trial of Iclusig (Ponatinib)

ARIAD Pharmaceuticals Inc. announced that the first patient has been treated in its OPTIC (Optimizing Ponatinib Treatment In CML) trial of Iclusig® (ponatinib). This randomized, dose-ranging trial is designed to evaluate three starting doses of ponatinib in patients with refractory, chronic-phase chronic myeloid leukemia (CP-CML) and is expected to inform the optimal use of Iclusig in these patients. Approximately 450 patients will be enrolled at clinical sites around the world. This study will enroll patients with CP-CML who are resistant to at least two approved TKIs. These patients will be randomized equally to receive once-daily administration of 45 mg (cohort A), 30 mg (cohort B) or 15 mg (cohort C) of ponatinib. Patients in cohorts A and B will have their daily dose reduced to 15 mg upon achievement of major cytogenetic response (MCyR). The primary endpoint of the trial is MCyR by 12 months for each cohort. Secondary endpoints include rate of vascular occlusive events in each dose cohort, rates of adverse events and rates of serious adverse events. Other secondary endpoints include cytogenetic, molecular and hematologic response rates, tolerability, duration of response, time to response, disease control rate, progression-free survival and overall survival. Preliminary data from the OPTIC trial is expected at the end of 2016.

Ariad Pharmaceuticals Inc. Reports Un-Audited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Revenue Guidance for the Year of 2015

Ariad Pharmaceuticals Inc. reported un-audited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported net loss of $63.2 million, or $0.33 per basic and diluted share on total revenue of $29.2 million, compared to a net loss of $56.9 million, or $0.30 per basic and diluted share on total revenue of $12.1 million, for the same period in 2014. For the six months, the company reported net loss of $115.8 million, or $0.62 per basic and diluted share on total revenue of $53.2 million, compared to a net loss of $106.7 million, or $0.57 per basic and diluted share on total revenue of $23.9 million, for the same period in 2014. Net cash used in operating activities was $78.6 million compared to $90.1 million reported for the last year. For the year, the company guidance for Iclusig net revenue remains unchanged at $130 million to $140 million and assumes completion of pricing and reimbursement negotiations in France and recognition of revenue, net of amounts to be refunded to the health authorities as a result of those negotiations.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
APS:GR €8.50 EUR +2.37

APS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Array BioPharma Inc $5.94 USD +0.10
Evotec AG €3.77 EUR -0.029
Exelixis Inc $6.05 USD -0.04
Insys Therapeutics Inc $33.83 USD +0.58
Pfizer Ltd/India 2,309 INR 0.00
View Industry Companies

Industry Analysis


Industry Average

Valuation APS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 13.8x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 10.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARIAD PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at